跳至主要内容
临床试验/NCT00653276
NCT00653276已完成1 期

An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects

Organon and Co0 个研究点目标入组 13 人开始时间: 2003年11月最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
13
主要终点
To evaluate the safety and tolerability of cyclosporine coadministered with ezetimibe vs. cyclosporine administered alone.

研究概览

简要总结

Study to determine the effect of multiple oral doses of ezetimibe on the pharmacokinetics of a single oral dose cyclosporine in young healthy males and females.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is male or female between 18 to 45 years of age
  • Subject is judged to be in good health on the basis of history, physical examination, and routine laboratory data

排除标准

  • Premenopausal women who are currently pregnant or who are currently nursing
  • Subjects with drug or substance abuse, poor mental function, history of major gastrointestinal abnormalities (stomach issues), or high cholesterol
  • Subject that has donated blood or has participated in another clinical trial within the last four weeks

研究组 & 干预措施

Treatment B

Active Comparator

Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.

干预措施: ezetimibe (Drug)

结局指标

主要结局

To evaluate the safety and tolerability of cyclosporine coadministered with ezetimibe vs. cyclosporine administered alone.

时间窗: Blood sampling will be conducted for 48 hours starting with the first cyclosporine dosing.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验